Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Tanaka T."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 41
Tytuł:
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach.
Autorzy:
Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Kariyama K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Tani J; Department of Gastroenterology and Neurology, Kagawa University, Kita-gun, Japan.
Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Fukunishi S; Department of Gastroenterology, Division of Hepatobiliary and Pancreatic Diseases, Hyogo Medical University, Nishinomiya, Japan.
Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Ochi H; Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Japan.
Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Japan.
Ogawa C; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
Yokohama K; Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Nishikawa H; Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Nishimura T; Department of Gastroenterology, Division of Hepatobiliary and Pancreatic Diseases, Hyogo Medical University, Nishinomiya, Japan.
Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Kawata K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kosaka H; Department of Surgery, Kansai Medical University, Hirakata, Japan.
Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Yata Y; Department of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
Ohama H; Department of Gastroenterology, Takarazuka City Hospital, Takarazuka, Japan.
Kuroda H; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
Tanaka K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Tanaka T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Tada F; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Nouso K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Morishita A; Department of Gastroenterology and Neurology, Kagawa University, Kita-gun, Japan.
Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Kaibori M; Department of Surgery, Kansai Medical University, Hirakata, Japan.
Iijima H; Department of Gastroenterology, Division of Hepatobiliary and Pancreatic Diseases, Hyogo Medical University, Nishinomiya, Japan.
Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Kumada T; Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Pokaż więcej
Corporate Authors:
Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Źródło:
Cancer medicine [Cancer Med] 2023 Dec; Vol. 12 (24), pp. 21680-21693. Date of Electronic Publication: 2023 Nov 21.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Humans ; Bevacizumab/adverse effects ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Serum wisteria floribunda agglutinin-positive human Mac-2 binding protein is unsuitable as a diagnostic marker of occult hepatocellular carcinoma in end-stage liver cirrhosis.
Autorzy:
Nagakawa K; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Hidaka M; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Hara T; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Matsushima H; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Imamura H; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Tanaka T; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Adachi T; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Soyama A; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Kanetaka K; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Eguchi S; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Nov 01; Vol. 18 (11), pp. e0293593. Date of Electronic Publication: 2023 Nov 01 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/complications
Carcinoma, Hepatocellular*/diagnosis
Liver Neoplasms*/diagnosis
Liver Neoplasms*/diagnostic imaging
Humans ; Plant Lectins/metabolism ; Receptors, N-Acetylglucosamine ; Liver Cirrhosis/complications ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/pathology ; Antigens, Neoplasm/metabolism ; Biomarkers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-term outcome and eligibility of radiofrequency ablation for hepatocellular carcinoma over 3.0 cm in diameter.
Autorzy:
Tanaka T; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan. .
Takata K; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Miyayama T; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Shibata K; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Fukuda H; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Yamauchi R; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Fukunaga A; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Yokoyama K; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Shakado S; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Sakisaka S; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Hirai F; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Sep 28; Vol. 13 (1), pp. 16286. Date of Electronic Publication: 2023 Sep 28.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Catheter Ablation*/adverse effects
Radiofrequency Ablation*
Humans ; Treatment Outcome ; Neoplasm Recurrence, Local/pathology ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression.
Autorzy:
Yamada K; Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.
Tanaka T; Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.
Kai K; Department of Pathology, Saga University Faculty of Medicine, Saga 849-8501, Japan.
Matsufuji S; Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.
Ito K; Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.
Kitajima Y; Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.; Department of Surgery, National Hospital Organization Higashisaga Hospital, Saga 849-0101, Japan.
Manabe T; Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.
Noshiro H; Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jul 17; Vol. 24 (14). Date of Electronic Publication: 2023 Jul 17.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/metabolism
Non-alcoholic Fatty Liver Disease*/complications
Non-alcoholic Fatty Liver Disease*/drug therapy
Liver Neoplasms*/metabolism
Mice ; Animals ; Farnesyltranstransferase ; Interleukin-6 ; Hypoxia-Inducible Factor 1, alpha Subunit ; Enzyme Inhibitors ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Inflammation/drug therapy ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma.
Autorzy:
Tachiiri T; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Nishiofuku H; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Maeda S; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Sato T; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Toyoda S; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Matsumoto T; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Chanoki Y; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Minamiguchi K; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Taiji R; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Kunichika H; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Yamauchi S; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Ito T; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Marugami N; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Tanaka T; Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara 634-8522, Japan.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 May 05; Vol. 30 (5), pp. 4779-4786. Date of Electronic Publication: 2023 May 05.
Typ publikacji:
Case Reports
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Chemoembolization, Therapeutic*/methods
Humans ; Ethiodized Oil/therapeutic use
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Less demand on stem cell marker-positive cancer cells may characterize metastasis of colon cancer.
Autorzy:
Kaida T; Department of Surgery, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan.; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Fujiyama Y; Department of Surgery, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan.; Department of General Pediatric and Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Soeno T; Department of Surgery, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan.; Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Yokota M; Department of Surgery, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan.; Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Nakamoto S; Department of General Pediatric and Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Goto T; Department of Surgery, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan.; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Watanabe A; Department of Surgery, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan.; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Okuno K; Department of Surgery, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan.; Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Nie Y; Department of Surgery, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan.; Department of General Pediatric and Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Fujino S; Department of Surgery, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan.; Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Yokota K; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Harada H; Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Tanaka Y; Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Tanaka T; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Yokoi K; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Kojo K; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Miura H; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Yamanashi T; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Sato T; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Sasaki J; Multidisciplinary Cancer Care and Treatment Center, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Sangai T; Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Hiki N; Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Kumamoto Y; Department of General Pediatric and Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Naitoh T; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Yamashita K; Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.; Division of Advanced Surgical Oncology, Research and Development Center for New Frontiers, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Apr 25; Vol. 18 (4), pp. e0277395. Date of Electronic Publication: 2023 Apr 25 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Colonic Neoplasms*/pathology
Liver Neoplasms*/pathology
Humans ; Hyaluronan Receptors/genetics ; Hyaluronan Receptors/metabolism ; Protein Isoforms/genetics ; Neoplastic Stem Cells/metabolism ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; AC133 Antigen/genetics ; AC133 Antigen/metabolism ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study.
Autorzy:
Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Kariyama K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Tani J; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Fukunishi S; Premier Departmental Research of Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Ochi H; Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Ogawa C; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
Nishimura T; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Kawata K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kosaka H; Department of Surgery, Kansai Medical University, Hirakata, Japan.
Tanaka T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Ohama H; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Nouso K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Morishita A; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Joko K; Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Kaibori M; Department of Surgery, Kansai Medical University, Hirakata, Japan.
Iijima H; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Kumada T; Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Pokaż więcej
Corporate Authors:
Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Źródło:
Cancer medicine [Cancer Med] 2023 Mar; Vol. 12 (5), pp. 5293-5303. Date of Electronic Publication: 2022 Oct 13.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Humans ; Bevacizumab/adverse effects ; Retrospective Studies ; East Asian People
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
Autorzy:
Tomonari T; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Tani J; Department of Gastroenterology and Neurology, Kagawa University Graduate School of Medicine, Kagawa, Japan.
Sato Y; Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Tanaka H; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Tanaka T; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Taniguchi T; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Asahiro M; Department of Gastroenterology and Neurology, Kagawa University Graduate School of Medicine, Kagawa, Japan.
Okamoto K; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Sogabe M; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Miyamoto H; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Muguruma N; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Masaki T; Department of Gastroenterology and Neurology, Kagawa University Graduate School of Medicine, Kagawa, Japan.
Takayama T; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Feb; Vol. 12 (3), pp. 2646-2657. Date of Electronic Publication: 2022 Aug 14.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*
Liver Neoplasms*
Humans ; Bevacizumab ; Albumins ; Bilirubin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.
Autorzy:
Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Gunma, Japan.
Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Kariyama K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Tani J; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Fukunishi S; Premier Departmental Research of Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Ochi H; Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Ogawa C; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
Nishimura T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Japan.
Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Kawata K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kosaka H; Department of Surgery, Kansai Medical University, Hirakata, Japan.
Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Tanaka T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Ohama H; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Nouso K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Morishita A; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Kaibori M; Department of Surgery, Kansai Medical University, Hirakata, Japan.
Iijima H; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Japan.
Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Kumada T; Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Pokaż więcej
Corporate Authors:
Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Źródło:
Cancer medicine [Cancer Med] 2023 Feb; Vol. 12 (4), pp. 4259-4269. Date of Electronic Publication: 2022 Sep 26.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Humans ; Prognosis ; Bevacizumab/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan.
Autorzy:
Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Kariyama K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Japan.
Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Japan.
Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Shibata H; Department of Gastroenterology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Tanaka T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Nouso K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Kosaka H; Department of Surgery, Kansai Medical University, Hirakata, Japan.
Kaibori M; Department of Surgery, Kansai Medical University, Hirakata, Japan.
Kumada T; Department of Nursing, Gifu Kyoritsu University, Japan.
Pokaż więcej
Corporate Authors:
Real-life Practice Experts for HCC (RELPEC) Study Group
Źródło:
Cancer medicine [Cancer Med] 2023 Jan; Vol. 12 (1), pp. 345-357. Date of Electronic Publication: 2022 May 24.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/diagnosis
Carcinoma, Hepatocellular*/epidemiology
Carcinoma, Hepatocellular*/therapy
Liver Neoplasms*/diagnosis
Liver Neoplasms*/epidemiology
Liver Neoplasms*/therapy
Humans ; Middle Aged ; Aged, 80 and over ; Retrospective Studies ; Japan/epidemiology ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Autorzy:
Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Kumada T; Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Kariyama K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Tani J; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Fukunishi S; Department of Gastroenterology, Osaka Medical and Phamaceutical University, Osaka, Japan.
Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Ochi H; Hepato-Biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Ogawa C; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
Nishimura T; Department of Gastroenterology and Hepatology, Hyogo College of Medicine, Hyogo, Japan.
Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Gunma, Japan.
Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Kawata K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Kosaka H; Department of Surgery, Kansai Medical University, Hirakata, Japan.
Shibata H; Department of Gastroenterology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Aoki T; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Tanaka T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Ohama H; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.; Department of Gastroenterology, Osaka Medical and Phamaceutical University, Osaka, Japan.
Nouso K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Morishita A; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Joko K; Hepato-Biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
Iijima H; Department of Gastroenterology and Hepatology, Hyogo College of Medicine, Hyogo, Japan.
Kaibori M; Department of Surgery, Kansai Medical University, Hirakata, Japan.
Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Pokaż więcej
Corporate Authors:
Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Źródło:
Cancer medicine [Cancer Med] 2023 Jan; Vol. 12 (1), pp. 325-334. Date of Electronic Publication: 2022 Jun 03.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Chemoembolization, Therapeutic*
Liver Neoplasms*/drug therapy
Humans ; Prognosis ; Bevacizumab/adverse effects ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
Autorzy:
Shimose S; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan. shimose_.
Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, 790-0024, Japan.
Tanaka M; Clinical Research Center, Yokokura Hospital, Miyama, Fukuoka, 839-0295, Japan.
Iwamoto H; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.; Iwamoto Internal Medical Clinic, Kitakyusyu, 802-0832, Japan.
Tanaka T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, 790-0024, Japan.
Noguchi K; Department of Gastroenterology, Omuta City Hospital, Omuta, 836-0861, Japan.
Aino H; Division of Gastroenterology, Department of Medicine, Social Insurance Tagawa Hospital, Tagawa, 826-0023, Japan.
Yamaguchi T; Iwamoto Internal Medical Clinic, Kitakyusyu, 802-0832, Japan.
Itano S; Department of Gastroenterology, Kurume Central Hospital, Kurume, 830-0001, Japan.
Suga H; Department of Gastroenterology and Hepatology, Yanagawa Hospital, Yanagawa, 832-0077, Japan.
Niizeki T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Moriyama E; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Shirono T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Noda Y; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Kamachi N; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Okamura S; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Nakano M; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Kawaguchi T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Kuromatsu R; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Koga H; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Torimura T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Oct 11; Vol. 12 (1), pp. 17018. Date of Electronic Publication: 2022 Oct 11.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Aging ; Bilirubin ; Humans ; Retrospective Studies ; Serum Albumin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
Autorzy:
Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.; Department of Internal medicine, Division of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
Kumada T; Department of Nursing, Gifu Kyoritsu University, Japan.
Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Kariyama K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Tani J; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Fukunishi S; Premier Departmental Research of Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Ochi H; Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Japan.
Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Japan.
Ogawa C; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
Nishimura T; Department of Internal medicine, Division of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Kawata K; Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Tanaka T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Ohama H; Premier Departmental Research of Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Nouso K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Morishita A; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Joko K; Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Iijima H; Department of Internal medicine, Division of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Pokaż więcej
Corporate Authors:
Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group
Źródło:
Cancer medicine [Cancer Med] 2022 Oct; Vol. 11 (20), pp. 3796-3808. Date of Electronic Publication: 2022 Apr 19.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/etiology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/etiology
Humans ; Middle Aged ; Aged ; Bevacizumab/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Proteinuria/chemically induced
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
Autorzy:
Shindo T; Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Maehana T; Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Tanaka T; Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Hashimoto K; Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Kobayashi K; Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Takahashi A; Department of Urology, Hakodate Koseiin Hakodate Goryoukaku Hospital, Hakodate, Japan.
Hotta H; Department of Urology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan.
Kunishima Y; Department of Urology, Sunagawa City Medical Center, Sunagawa, Japan.
Taguchi K; Department of Urology, Oji General Hospital, Tomakomai, Japan.
Tachiki H; Department of Urology, Steel Memorial Muroran Hospital, Muroran, Japan.
Ito N; Department of Urology, NTT East Corporation Sapporo Hospital, Sapporo, Japan.
Matsukawa M; Department of Urology, Takikawa Municipal Hospital, Takikawa, Japan.
Kato R; Department of Urology, Muroran City General Hospital, Muroran, Japan.
Miyamoto S; Department of Urology, Japanese Red Cross Kushiro Hospital, Kushiro, Japan.
Hinotsu S; Department of Biostatistics, Sapporo Medical University School of Medicine, Sapporo, Japan.
Masumori N; Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Pokaż więcej
Źródło:
International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2022 Sep; Vol. 29 (9), pp. 1010-1016. Date of Electronic Publication: 2022 Jun 02.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Carcinoma, Transitional Cell*/pathology
Liver Neoplasms*/drug therapy
Urinary Bladder Neoplasms*
Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cisplatin ; Deoxycytidine/analogs & derivatives ; Humans ; Retrospective Studies ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Autorzy:
Tanaka T; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
Takata K; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
Yokoyama K; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
Fukuda H; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
Yamauchi R; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
Fukunaga A; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
Shakado S; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
Sakisaka S; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
Hirai F; Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Jul 08; Vol. 29 (7), pp. 4799-4810. Date of Electronic Publication: 2022 Jul 08.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Albumins/therapeutic use ; Antibodies, Monoclonal, Humanized ; Bevacizumab/pharmacology ; Bevacizumab/therapeutic use ; Bilirubin/therapeutic use ; Humans ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Autorzy:
Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, 1-12-1 Shimoteno, Himeji, Hyogo, 670-8540, Japan. .
Kumada T; Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Touon, Ehime, Japan.
Kariyama K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Tani J; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Fukunishi S; Department of Gastroenterology, Osaka Medical College, Osaka, Japan.
Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Ochi H; Hepato-Biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Kawata K; Department of Hepatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Tanaka T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Ohama H; Department of Gastroenterology, Osaka Medical College, Osaka, Japan.
Nouso K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Morishita A; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Aoki T; Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan.
Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Touon, Ehime, Japan.
Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, 1-12-1 Shimoteno, Himeji, Hyogo, 670-8540, Japan.
Joko K; Hepato-Biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Touon, Ehime, Japan.
Kudo M; Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 May 19; Vol. 12 (1), pp. 8421. Date of Electronic Publication: 2022 May 19.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Albumins ; C-Reactive Protein/metabolism ; Humans ; Phenylurea Compounds ; Quinolines ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment.
Autorzy:
Chuma M; Gastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
Yokoo H; Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery and Transplant Surgery, Asahikawa Medical University, Asahikawa 078-8510, Japan.
Hiraoka A; Gastroenterological Center, Ehime Prefectural Central Hospital, Matsuyama 790-0024, Japan.
Ueda K; Diagnostic Imaging Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
Yokoyama T; Gastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo 006-8555, Japan.
Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa 277-0863, Japan.
Uojima H; Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara 252-0375, Japan.
Kobayashi S; Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama 241-8585, Japan.
Hattori N; Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
Okubo T; Division of Gastroenterology, Nippon Medical School, Chiba Hokusoh Hospital, Inzai 270-1694, Japan.
Atsukawa M; Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo 113-8603, Japan.
Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata 950-1104, Japan.
Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu 760-8557, Japan.
Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu 760-8557, Japan.
Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki 503-8502, Japan.
Tada T; Department of Internal medicine, Japanese Red Cross Himeji Hospital, Himeji 670-8540, Japan.
Saito Y; Department of Gastroenterology, Asahikawa-Kosei General Hospital, Asahikawa 078-8211, Japan.
Hirose S; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Tokai University School of Medicine, Isehara 259-1193, Japan.
Tanaka T; Gastroenterological Center, Ehime Prefectural Central Hospital, Matsuyama 790-0024, Japan.
Takeda K; Gastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
Otani M; Diagnostic Pathology, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
Sekikawa Z; Diagnostic Radiology, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
Watanabe T; Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
Hidaka H; Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara 252-0375, Japan.
Morimoto M; Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama 241-8585, Japan.
Numata K; Gastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
Kagawa T; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Tokai University School of Medicine, Isehara 259-1193, Japan.
Sakamoto M; Department of Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Kumada T; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo 006-8555, Japan.; Faculty of Nursing, Gifu Kyoritsu University, Ogaki 503-0001, Japan.
Maeda S; Department of Gastroenterology, Yokohama City University Hospital, Yokohama 236-0004, Japan.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 May 04; Vol. 29 (5), pp. 3259-3271. Date of Electronic Publication: 2022 May 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/diagnostic imaging
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/diagnostic imaging
Liver Neoplasms*/drug therapy
Humans ; Necrosis ; Phenylurea Compounds ; Quinolines ; Tomography, X-Ray Computed/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.
Autorzy:
Murakami K; Department of Nuclear Receptor Medicine, Laboratories for Systems Biology and Medicine (LSBM) at the Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Tokyo 153-8904, Japan.; Pharmaceutical Division, Kowa Company, Ltd., Tokyo 189-0022, Japan.
Sasaki Y; Department of Nuclear Receptor Medicine, Laboratories for Systems Biology and Medicine (LSBM) at the Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Tokyo 153-8904, Japan.; Pharmaceutical Division, Kowa Company, Ltd., Tokyo 189-0022, Japan.
Asahiyama M; Pharmaceutical Division, Kowa Company, Ltd., Tokyo 189-0022, Japan.
Yano W; Pharmaceutical Division, Kowa Company, Ltd., Tokyo 189-0022, Japan.
Takizawa T; Pharmaceutical Division, Kowa Company, Ltd., Tokyo 189-0022, Japan.
Kamiya W; Department of Nuclear Receptor Medicine, Laboratories for Systems Biology and Medicine (LSBM) at the Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Tokyo 153-8904, Japan.
Matsumura Y; Division of Metabolic Medicine, Laboratories for Systems Biology and Medicine (LSBM) at the Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Tokyo 153-8904, Japan.
Anai M; Department of Nuclear Receptor Medicine, Laboratories for Systems Biology and Medicine (LSBM) at the Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Tokyo 153-8904, Japan.
Osawa T; Division of Integrative Nutriomics and Oncology, Laboratories for Systems Biology and Medicine (LSBM) at the Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Tokyo 153-8904, Japan.
Fruchart JC; R3i Foundation, Picassoplatz 8, 4010 Basel, Switzerland.
Fruchart-Najib J; R3i Foundation, Picassoplatz 8, 4010 Basel, Switzerland.
Aburatani H; Genome Science Division, Laboratories for Systems Biology and Medicine (LSBM) at the Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Tokyo 153-8904, Japan.
Sakai J; Division of Metabolic Medicine, Laboratories for Systems Biology and Medicine (LSBM) at the Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Tokyo 153-8904, Japan.; Tohoku University Graduate School of Medicine, Division of Molecular Physiology and Metabolism, Sendai 980-8575, Japan.
Kodama T; Department of Nuclear Receptor Medicine, Laboratories for Systems Biology and Medicine (LSBM) at the Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Tokyo 153-8904, Japan.
Tanaka T; Department of Nuclear Receptor Medicine, Laboratories for Systems Biology and Medicine (LSBM) at the Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Tokyo 153-8904, Japan.
Pokaż więcej
Źródło:
Cells [Cells] 2022 Feb 18; Vol. 11 (4). Date of Electronic Publication: 2022 Feb 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/prevention & control
Liver Neoplasms*/prevention & control
Non-alcoholic Fatty Liver Disease*/drug therapy
Non-alcoholic Fatty Liver Disease*/metabolism
Animals ; Benzhydryl Compounds/pharmacology ; Benzoxazoles/pharmacology ; Butyrates/pharmacology ; Glucosides/pharmacology ; Mice ; PPAR alpha/antagonists & inhibitors ; Sodium-Glucose Transporter 2 Inhibitors/pharmacology ; Triglycerides
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Autorzy:
Rapposelli IG; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'-IRST, Meldola, Italy.
Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Shimose S; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Burgio V; Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy.
Kumada T; Faculty of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Iwamoto H; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Niizeki T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Koga H; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Torimura T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Iavarone M; Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Tortora R; Liver Unit, Cardarelli Hospital, Naples, Italy.
Campani C; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Lonardi S; Early Phase Clinical Trial Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.; Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Tamburini E; Department of Medical Oncology, Card. G. Panico Hospital of Tricase, Tricase, Italy.
Piscaglia F; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, Azienda Ospedaliero Universitaria di Bologna, Italy.
Masi G; Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Cabibbo G; Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy.
Giuseppe Foschi F; Department of Internal Medicine, Faenza Hospital, AUSL Romagna, Faenza, Italy.
Silletta M; Medical Oncology Unit, University Campus Bio-Medico, Rome, Italy.
Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Kariyama K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Shibata H; Department of Gastroenterology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Ochi H; Hepato-biliary Center, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Fukunishi S; Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Japan.
Ohama H; Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Japan.
Kawata K; Hepatology Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Tani J; Department of Gastroenterology and Neurology, Kagawa University School of Medicine, Kagawa, Japan.
Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Nouso K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Tanaka T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Joko K; Hepato-biliary Center, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Rimini M; Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Ratti F; Hepatobiliary Surgery Division, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Aldrighetti L; Hepatobiliary Surgery Division, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Cascinu S; Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy.
Casadei-Gardini A; Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy.
Pokaż więcej
Źródło:
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2021 Dec; Vol. 41 (12), pp. 2997-3008. Date of Electronic Publication: 2021 Jul 22.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*
Liver Neoplasms*
Quinolines*/adverse effects
Humans ; Phenylurea Compounds/adverse effects ; Quality of Life ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Autorzy:
Shimose S; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Nakano M; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Iwamoto H; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.; Iwamoto Internal Medical Clinic, Kitakyusyu, Japan.
Tanaka M; Clinical Research Center, Yokokura Hospital, Miyama, Fukuoka, Japan.
Tanaka T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Noguchi K; Department of Gastroenterology, Omuta City Hospital, Omuta, Japan.
Aino H; Division of Gastroenterology, Department of Medicine, Social Insurance Tagawa Hospital, Tagawa, Japan.
Ogata K; Department of Gastroenterology, Kurume University Medical Center, Kurume, Japan.
Kajiwara M; Department of Gastroenterology, Chikugo City Hospital, Chikugo, Japan.
Itano S; Department of Gastroenterology, Kurume Central Hospital, Kurume, Japan.
Yokokura Y; Clinical Research Center, Yokokura Hospital, Miyama, Fukuoka, Japan.
Yamaguchi T; Iwamoto Internal Medical Clinic, Kitakyusyu, Japan.
Kawano H; Department of Gastroenterology, St. Mary's Hospital, Kurume, Japan.
Matsukuma N; Department of Gastroenterology, Kurume General Hospital, Kurume, Japan.
Suga H; Department of Gastroenterology and Hepatology, Yanagawa Hospital, Yanagawa, Japan.
Niizeki T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Shirono T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Noda Y; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Kamachi N; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Okamura S; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Kawaguchi T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Koga H; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Torimura T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2021 Dec; Vol. 10 (23), pp. 8530-8541. Date of Electronic Publication: 2021 Oct 24.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Sorafenib/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Hepatocellular/pathology ; Female ; Humans ; Japan ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease/etiology ; Progression-Free Survival ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 41

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies